Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women

Bone

Volumn 56, Issue 1, 2013, Pages 154-162

  Caltabiano, Stephen ^a   Dollery, Colin T ^a   Hossain, Mohammad ^a   Kurtinecz, Milena T ^a   Desjardins, John P ^a   Favus, Murray J ^b   Kumar, Rajiv ^c   Fitzpatrick, Lorraine A ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Calcilytic; Calcium homeostasis; Calcium sensing receptor; Kidney; Parathyroid hormone; Postmenopausal osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RONACALERET; VITAMIN D;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MECHANISM; EVENING DOSAGE; FEMALE; HUMAN; HYPERPARATHYROIDISM; MORNING DOSAGE; PARALLEL DESIGN; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

CALCILYTIC; CALCIUM HOMEOSTASIS; CALCIUM-SENSING RECEPTOR; KIDNEY; PARATHYROID HORMONE; POSTMENOPAUSAL OSTEOPOROSIS;

ADULT; AGED; CALCIUM; DEMOGRAPHY; FEMALE; HUMANS; HYPERCALCEMIA; INDANS; KIDNEY; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PHENYLPROPIONATES; PHOSPHATES; POSTMENOPAUSE; PROCOLLAGEN; RECEPTORS, CALCIUM-SENSING; TIME FACTORS;

EID: 84879547184     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.05.021     Document Type: Article

References (20)

1. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001, 81:239-297.
2. 2+-sensing receptors - an overview. Cell Calcium 2004, 35:183-196.
3. Goodman W.G. Calcium-sensing receptors. Semin Nephrol 2004, 24:17-24.
4. Riccardi D., Brown E.M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010, 298:F485-F499.
5. Magno A.L., Ward B.K., Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endocr Rev 2011, 32:3-30.
6. Quarles L.D. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003, 12:349-355.
7. Chen R.A., Goodman W.G. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004, 286:F1005-F1011.
8. Ward D.T., Riccardi D. New concepts in calcium-sensing receptor pharmacology and signalling. Br J Pharmacol 2012, 165:35-48.
9. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Papapoulos S., Bone H.G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96:2441-2449.
10. Neer R.N., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.-Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
11. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Fuerst T., Engelke K., et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 2012, 27:255-262.
12. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
13. Heaney R.P., Recker R.R., Ryan R.A. Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999, 9:13-18.
14. Schwietert H.R., Groen E.W.J., Sollie F.A.E., Jonkman J.H.G. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997, 61:360-376.
15. Miller P.D., Bilezikien J.P., Diaz-Curiel M., et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535-3541.
16. Silverberg S.J., Bone H.G., Marriott T.B., et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997, 337:1506-1510.
17. Kohri K., Kataoka K., Yachiku S., Kurita T.-A., Sonoda T. Changes in cyclic AMP and electrolytes after parathyroidectomy in primary hyperparathyroidism. Clin Endocrinol 1983, 18:371-376.
18. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 2007, 146:326-339.
19. Plotkin H., Gundberg C., Mitnick M., Stewart A.F. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 1998, 83:2786-2791.
20. 2+-sensing receptor cDNA from human kidney. Biochem Biophys Res Commun 1995, 214:524-529.